Shares of Ironwood (IRWD) are moving higher after its partner AbbVie (ABBV) reported Q3 Linzess sales of $315M, which beat Citizens JMP’s estimate of $241M. Analyst Jason Butler views the sales beat as a “clear positive” for Ironwood as it continues to evaluate strategic alternatives. Ironwood in late day trading is up 24%, or 36c to $1.86.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD: